Progressive Multifocal Leukoencephalopathy: Current Insights

References

• Åström KE, Mancall EL, Richardson EP Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and hodgkin’s disease. Brain. 1958;81:1.13523001
   PubMed Web of Science ®Google Scholar
• Zaheer F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3:5. doi:10.1177/204209861245384925083221
   PubMedGoogle Scholar
• Anton R, Haas M, Arlett P, et al. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators’ perspective. Clin Pharmacol Ther. 2017;102:283–289. doi:10.1002/cpt.v102.228001298
   PubMed Web of Science ®Google Scholar
• Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24:4. doi:10.1177/107327481772990128178723
   PubMed Web of Science ®Google Scholar
• Lindå H, von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol. 2013. doi:10.3389/fneur.2013.00011
   Web of Science ®Google Scholar
• Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. 2013;84:10. doi:10.1136/jnnp-2013-30489722767385
   PubMed Web of Science ®Google Scholar
• Dang X, Wüthrich C, Gordon J, Sawa H, Koralnik IJ. JC virus encephalopathy is associated with a novel agnoprotein-deletion JCV variant. PLoS One. 2012;7:4. doi:10.1371/journal.pone.0035793
   Web of Science ®Google Scholar
• Takahashi K, Sekizuka T, Fukumoto H, et al. Deep-sequence identification and role in virus replication of a JC virus quasispecies in patients with progressive multifocal leukoencephalopathy. J Virol. 2016;91:1.
   Web of Science ®Google Scholar
• Seppälä HM, Helanterä IT, Laine PKS, et al. Archetype JC Polyomavirus (JCPyV) Prevails in a Rare Case of JCPyV nephropathy and in stable renal transplant recipients with JCPyV viruria. J Infect Dis. 2017;216:8. doi:10.1093/infdis/jix435
   Web of Science ®Google Scholar
• Bellizzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18:1. doi:10.1007/s13365-012-0080-722290500
   PubMed Web of Science ®Google Scholar
• Auer M, Hegen H, Sellner J, et al. Conversion and reversion of anti‐John Cunningham virus antibody serostatus: a prospective study. Brain Behav. 2019;9:7.
   Web of Science ®Google Scholar
• Durali D, de Goër de Herve MG, Gasnault J, Taoufik Y. B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol. 2015;6. doi:10.3389/fimmu.2015.00241
   Web of Science ®Google Scholar
• Sanjo N, Nose Y, Shishido-Hara Y, et al. A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy. J Neurol. 2019;266:2. doi:10.1007/s00415-018-9140-0
   Web of Science ®Google Scholar
• Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78:22. doi:10.1212/WNL.0b013e3182583022
   Web of Science ®Google Scholar
• Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. 2013;84:11. doi:10.1136/jnnp-2012-304332
   Web of Science ®Google Scholar
• Outteryck O, Zéphir H, Salleron J, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. 2014;20:7. doi:10.1177/1352458513505353
   Web of Science ®Google Scholar
• Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2015;21:12. doi:10.1177/1352458514567728
   Web of Science ®Google Scholar
• Delbue S, Ferraresso M, Ghio L, et al. A review on JC virus infection in kidney transplant recipients. Clin Dev Immunol. 2013;2013:1–7. doi:10.1155/2013/926391
   Google Scholar
• Corbridge SM, Rice RC, Bean LA, et al. JC virus infection of meningeal and choroid plexus cells in patients with progressive multifocal leukoencephalopathy. J Neurovirol. 2019;25:520–524. doi:10.1007/s13365-019-00753-y31025264
   PubMed Web of Science ®Google Scholar
• Tan CS, Koralnik IJ. Beyond progressive multifocal leukoencephalopathy: expanded pathogenesis of JC virus infection in the central nervous system. Lancet Neurol. 2010;9:4.20083022
   PubMed Web of Science ®Google Scholar
• Khoury MN, Alsop DC, Agnihotri SP, et al. Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol. 2014;75:5. doi:10.1002/ana.v75.5
   Web of Science ®Google Scholar
• White FA, Ishaq M, Stoner GL, Frisque RJ. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol. 1992;66:10.
   Web of Science ®Google Scholar
• Wüthrich C, Koralnik IJ. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2012;71:1. doi:10.1097/NEN.0b013e31823ede59
   Web of Science ®Google Scholar
• Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;12:75.
   Google Scholar
• Casado JL, Corral I, García J, et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis. 2014;33:2. doi:10.1007/s10096-013-1941-6
   Web of Science ®Google Scholar
• Iacobaeus E, Burkill S, Bahmanyar S, et al. The national incidence of PML in Sweden, 1988–2013. Neurology. 2018;90:e498–e506. doi:10.1212/WNL.000000000000492629321229
   PubMed Web of Science ®Google Scholar
• Sipilä JOT, Soilu-Hänninen M, Rautava P, Kytö V. Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study. J Neurol. 2019;266:2. doi:10.1007/s00415-018-09167-y
   Web of Science ®Google Scholar
• Kartau M, Verkkoniemi-Ahola A, Paetau A, et al. The incidence and predisposing factors of John Cunningham virus-induced progressive multifocal leukoencephalopathy in Southern Finland: a population-based study. Open Forum Infect Dis. 2019;6:2. doi:10.1093/ofid/ofz024
   Web of Science ®Google Scholar
• Neil EC, DeAngelis LM. Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv. 2017;1:23. doi:10.1182/bloodadvances.2017008201
   Web of Science ®Google Scholar
• Adrianzen Herrera D, Ayyappan S, Jasra S, et al. Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant – a case series. Leuk Lymphoma. 2019;60:2. doi:10.1080/10428194.2018.1474523
   Web of Science ®Google Scholar
• Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120:16. doi:10.1002/cncr.28712
   Web of Science ®Google Scholar
• García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol. 2005;80:4. doi:10.1002/ajh.20492
   Web of Science ®Google Scholar
• Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin. 2008;26:3. doi:10.1016/j.ncl.2008.03.007
   Web of Science ®Google Scholar
• d’Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55:3. doi:10.1002/ana.10788
   Web of Science ®Google Scholar
• Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199:1. doi:10.1086/59529919086812
   PubMed Web of Science ®Google Scholar
• Gasnault J, Costagliola D, Hendel-Chavez H, et al. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One. 2011;6:6. doi:10.1371/journal.pone.0020967
   Web of Science ®Google Scholar
• Falcó V, Olmo M, del Saz SV, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr. 2008;49:1. doi:10.1097/QAI.0b013e31817bec6418667918
   PubMed Web of Science ®Google Scholar
• Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol. 2011;70:2. doi:10.1002/ana.v70.2
   Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Ayala E, Greene J. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007;39(2):101–117.17143300
   PubMed Web of Science ®Google Scholar
• Steurer M, Clausen J, Gotwald T. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation. 2003;76:435–436. doi:10.1097/01.TP.0000078897.11633.5F12883208
   PubMed Web of Science ®Google Scholar
• Pruitt AA, Graus F, Rosenfeld MR. Neurological complications of transplantation. Neurohospitalist. 2013;3:1.
   Google Scholar
• Clavel G, Moulignier A, Semerano L. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments. Joint Bone Spine. 2017;84:6. doi:10.1016/j.jbspin.2017.03.002
   Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60. doi:10.1002/art.24966
   Web of Science ®Google Scholar
• Brandao M, Damasio J, Marinho A, et al. Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia. Clin Rev Allergy Immunol. 2012;43:302–307. doi:10.1007/s12016-012-8327-x22674017
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Néel A, Lecouffe-Desprets M, et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology. 2014;82:15. doi:10.1212/WNL.000000000000031824306000
   PubMed Web of Science ®Google Scholar
• Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine. 2012;79:351–355. doi:10.1016/j.jbspin.2011.11.00222281228
   PubMed Web of Science ®Google Scholar
• Bag AK, Curé JK, Chapman PR, Roberson GH, Shah R. JC virus infection of the brain. AJNR Am J Neuroradiol. 2010;31:9. doi:10.3174/ajnr.A2035
   Web of Science ®Google Scholar
• Hadjadj J, Guffroy A, Delavaud C, et al. Progressive multifocal leukoencephalopathy in primary immunodeficiencies. J Clin Immunol. 2019;39:1. doi:10.1007/s10875-018-0578-8
   Web of Science ®Google Scholar
• Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppressio. J Neurol Neurosurg Psychiatry. 2010;81:3. doi:10.1136/jnnp.2009.18766620019217
   PubMed Web of Science ®Google Scholar
• Rosas MJ, Simões-Ribeiro F, An SF, Sousa N. Progressive multifocal leukoencephalopathy: unusual MRI findings and prolonged survival in a pregnant woman. Neurology. 1999;52:3. doi:10.1212/WNL.52.3.657
   Web of Science ®Google Scholar
• Stockhammer G, Poewe W, Wissel J, Kiechl U, Maier H, Felber S. Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder. Mov Disord. 2000;15:5. doi:10.1002/1531-8257(200009)15:5<>1.0.CO;2-S
   Web of Science ®Google Scholar
• Shepard HM, Phillips GL, Thanos CD, Feldmann M. Developments in therapy with monoclonal antibodies and related proteins. Clin Med. 2017;17:3. doi:10.7861/clinmedicine.17-3-220
   Web of Science ®Google Scholar
• Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68:9. doi:10.1001/archneurol.2011.103
   Google Scholar
• Yukitake M. Drug‐induced progressive multifocal leukoencephalopathy in multiple sclerosis: A comprehensive review. Clin Exp Neuroimmunol. 2018;9:37–47. doi:10.1111/cen3.2018.9.issue-S1
   Google Scholar
• Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system. Expert Opin Drug Saf. 2016;15:8. doi:10.1080/14740338.2016.1198775
   Web of Science ®Google Scholar
• Genentech. [Online] 9 30, 2019 Available from: https://www.ocrelizumabinfo.com/content/dam/gene/ocrelizumabinfo/pdfs/progressive-multifocal-leukoencephalopathy.pdf.
   Google Scholar
• Klotz L, Havla J, Schwab N, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:175628641983657. doi:10.1177/1756286419836571
   Web of Science ®Google Scholar
• Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90:e1815–e1821. doi:10.1212/WNL.000000000000552929669908
   PubMed Web of Science ®Google Scholar
• Gerevini S, Capra R, Bertoli D, Sottini A, Imberti L. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2019;25:8. doi:10.1177/1352458519832259
   Web of Science ®Google Scholar
• Lehmann HC, Krüger K, Fink GR, Schroeter M. Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy. J Neurol. 2015;262:3. doi:10.1007/s00415-014-7620-4
   Web of Science ®Google Scholar
• Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63. doi:10.1016/j.msard.2017.01.00628283109
   PubMed Web of Science ®Google Scholar
• von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:1. doi:10.1056/NEJMe020157
   Web of Science ®Google Scholar
• Maas RP, Muller-Hansma AH, Esselink RA, et al. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol. 2016;263:10. doi:10.1007/s00415-016-8217-x
   Web of Science ®Google Scholar
• Prosperini L, de Rossi N, Scarpazza C, et al. Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry. PLoS One. 2016;11:12. doi:10.1371/journal.pone.0168376
   Web of Science ®Google Scholar
• Prosperini L, Scarpazza C, Imberti L, Cordioli C, De Rossi N, Capra R. Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopath. J Neurovirol. 2017;23:5. doi:10.1007/s13365-017-0561-9
   Web of Science ®Google Scholar
• Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:11. doi:10.1016/S1474-4422(17)30282-X
   Web of Science ®Google Scholar
• Oshima Y, Tanimoto T, Yuji K, Tojo A. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler. 2019;25:8. doi:10.1177/1352458518786075
   Web of Science ®Google Scholar
• Hughes S. PML reported in patient receiving ocrelizumab. S.L. Available from: https://www.medscape.com/viewarticle/880654. Medscape 2017.
   Google Scholar
• Clifford DB, Gass A, Richert N, et al. Cases reported as progressive multifocal leukoencephalopathy in ocrelizumab-treated patients with multiple sclerosis. Poster session presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm; 2019.
   Google Scholar
• ocrelizumabinfo home page. F. Hoffmann La-Roche Ltd. [Online] 2019 Available from: https://www.ocrelizumabinfo.global.
   Google Scholar
• Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler. 2019;25:12. doi:10.1177/1352458519852100
   Web of Science ®Google Scholar
• Alstadhaug KB, Fykse Halstensen R, Odeh F. Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. J Clin Virol. 2017;88:17–20. doi:10.1016/j.jcv.2016.12.00528095350
   PubMed Web of Science ®Google Scholar
• Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013;80:1430–1438. doi:10.1212/WNL.0b013e31828c2fa123568998
   PubMed Web of Science ®Google Scholar
• Tan SC, Koralnik IJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases (Eighth Edition). SL: Elsevier Health Sciences; 2015.
   Google Scholar
• Williamson EML, Berger JR. Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics. 2017;14:961–973. doi:10.1007/s13311-017-0570-728913726
   PubMed Web of Science ®Google Scholar
• Scarpazza C. Early diagnosis of PML: results from the Italian cohort. [Online] 10 27, 2017 Available from: http://onlinelibrary.ectrims-congress.eu/ectrims/2017/ACTRIMS-ECTRIMS2017/200861/cristina.scarpazza.early.diagnosis.of.pml.results.from.the.italian.cohort.html.
   Google Scholar
• Berger JR. Progressive multifocal leukoencephalopathy. Handb Clin Neurol. 2014;123.
   Google Scholar
• Berger JR, Pall L, Lanska D. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4:1. doi:10.3109/135502898091134829531008
   PubMed Web of Science ®Google Scholar
• Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology. 2019;92:19. doi:10.1212/WNL.0000000000007451
   Web of Science ®Google Scholar
• Wattjes MP, Rovira À, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis–establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:10.
   Web of Science ®Google Scholar
• McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87(2):117–125.26492930
   PubMed Web of Science ®Google Scholar
• Yousry TA, Pelletier D, Cadavid D. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72:779–787. doi:10.1002/ana.v72.523280794
   PubMed Web of Science ®Google Scholar
• Shah R, Bag AK, Chapman PR, et al. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol. 2010;65:431–439. doi:10.1016/j.crad.2010.03.00120451009
   PubMed Web of Science ®Google Scholar
• Scholten P, Kralt P, Jacobs B. Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease. BMJ Case Rep. 2017;bcr-2017-220990. doi:10.1136/bcr-2017-220990
   Google Scholar
• Hodel J, Outteryck O, Dubron C, et al. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging. Radiology. 2016;278(3):863–872.26436861
   PubMed Web of Science ®Google Scholar
• Sanjo N, Kina S, Shishido-Hara Y, et al. Progressive multifocal leukoencephalopathy with balanced CD4/CD8 T-cell infiltration and good response to mefloquine treatment. Intern Med. 2016;55:2. doi:10.2169/internalmedicine.55.6051
   Web of Science ®Google Scholar
• Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77:11. doi:10.1212/WNL.0b013e31822e55e7
   Web of Science ®Google Scholar
• Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry. 2012;83:224–226. doi:10.1136/jnnp-2011-30051122013244
   PubMed Web of Science ®Google Scholar
• Adang L, Berger J. Progressive multifocal leukoencephalopathy. F1000Res. 2015;4. doi:10.12688/f1000research.7071.1
   PubMedGoogle Scholar
• Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–446. doi:10.1016/S1474-4422(10)70028-420298967
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M. Progressive multifocal leukeoncephalopathy consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8:6. doi:10.1177/1756285615602832
   Web of Science ®Google Scholar
• Jamilloux Y, Kerever S, Ferry T, Broussolle C, Honnorat J, Sève P. Treatment of progressive multifocal leukoencephalopathy with mirtazapine. Clin Drug Investig. 2016;36:10. doi:10.1007/s40261-016-0433-8
   Web of Science ®Google Scholar
• Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72:5. doi:10.1212/01.wnl.0000341766.59028.9d
   Web of Science ®Google Scholar
• Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Sierra Morales F. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019;6:5. doi:10.1002/acn3.2019.6.issue-5
   Web of Science ®Google Scholar
• Cortese I, Muranski P, Enose-Akahata Y, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380:1597–1605. doi:10.1056/NEJMoa181503930969503
   PubMed Web of Science ®Google Scholar
• Walter O, Treiner E, Bonneville F, et al. Treatment of progressive multifocal leukoencephalopathy with nivolumab. N Engl J Med. 2019;380:17. doi:10.1056/NEJMc1816198
   Web of Science ®Google Scholar
• Grimm J, Martin R, Combauzier B Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases. Patent WO2014/102399 Al 2014.
   Google Scholar
• Muftuoglu M, Olson A, Marin D, et al. Allogeneic BK virus–specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med. 2018;379:15. doi:10.1056/NEJMoa1801540
   Web of Science ®Google Scholar
• Vermersch PD, Kappos LM, Gold RM, et al. Effective therapy for PML by achieving immune reconstitution has resulted in survival as 70–80% in both HIV and natalizumab associated PML. Neurology. 2011;76:20.
   Google Scholar
• Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76:20. doi:10.1212/WNL.0b013e31821a446b
   Web of Science ®Google Scholar
• Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2010;81:11. doi:10.1136/jnnp.2009.179002
   Web of Science ®Google Scholar
• Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72:17. doi:10.1212/01.wnl.0000343510.08643.74
   Web of Science ®Google Scholar
• Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology. 2012;79:23. doi:10.1212/WNL.0b013e3182768983
   Web of Science ®Google Scholar
• Giacomini PS, Rozenberg A, Metz I, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014;370:5. doi:10.1056/NEJMc1304828
   Web of Science ®Google Scholar
• Nishigori R, Warabi Y, Shishido-Hara Y, et al. Inflammatory cerebellar PML with a CD4/CD8 ratio of 2.9 showed a favorable prognosis in a patient with rheumatoid arthritis: a case report. Intern Med. 2019;58:3323–3329. doi:10.2169/internalmedicine.3038-1931366796
   PubMed Web of Science ®Google Scholar
• Fournier A, Martin-Blondel G, Lechapt-Zalcman E, et al. Immune reconstitution inflammatory syndrome unmasking or worsening AIDS-related progressive multifocal leukoencephalopathy: a literature review. Front Immunol. 2017;8. doi:10.3389/fimmu.2017.00577
   Web of Science ®Google Scholar
• Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patientswith MS is reduced with extended interval dosing. Neurology. 2019;93:15. doi:10.1212/WNL.000000000000793831142632
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Updated recommendations to minimise the risk of the rare brain infection PML with tecfidera. [Online] 2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/10/WC500196017.pdf.
   Google Scholar
• New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with gilenya. [Online] 2015 Available from: https://www.ema.europa.eu/en/documents/press-release/new-recommendations-minimise-risks-rare-brain-infection-pml-type-skin-cancer-gilenya_en.pdf.
   Google Scholar
• Tuccori M, Focosi D, Blandizzi C, Del Tacca M, Petrini M. Re: rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101:18. doi:10.1093/jnci/djp256
   Google Scholar
• Bower JH, Hammack JE, McDonnell SK, Tefferi A. The neurologic complications of B-cell chronic lymphocytic leukemia. Neurology. 1997;48:2. doi:10.1212/WNL.48.2.4079008484
   PubMed Web of Science ®Google Scholar
• van Rijswijk RE, Verbeek J, Haanen C, Dekker AW, van Daal WA, van Peperzeel HA. Major complications and causes of death in patients treated for hodgkin’s disease. J Clin Oncol. 1987;5:10. doi:10.1200/JCO.1987.5.10.16242433406
   PubMed Web of Science ®Google Scholar